Cheuk To Chung

Cheuk To Chung

Auto-generated profile, based on publicly available information

Cheuk To Chung

Cardiovascular Analytics Group

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
OCOscar Hou‐In Chou
Oscar Hou‐In Chou
ZLZhiyao Luo
Zhiyao Luo
CCCheuk To Skylar Chung
Cheuk To Skylar Chung
JCJeffrey Shi Kai Chan
Jeffrey Shi Kai Chan
HLHuixian Li
Huixian Li
Jiandong ZhouJiandong Zhou
Jiandong Zhou
Background: Sodium‐glucose cotransporter‐2 inhibitors (SGLT2Is), dipeptidyl peptidase‐4 inhibitors (DPP4Is), and glucagon‐like peptide‐1 receptor agonists have been associated with improved cardiovascular outcomes and prognosis. The comparative risks of new‐onset peripheral artery disease (PAD) between these medications remain unknown. This real‐world study compared the risks of PAD in patients exposed to SGLT2I and DPP4I. METHODS AND RESULTS: This was a retrospective population‐based cohort study of patients with type 2 diabetes on either an SGLT2I or a DPP4I between January 1, 2015, and December 31, 2015, using a territory‐wide database from Hong Kong. The primary outcome was new‐onset PAD. The secondary outcomes were cardiovascular hospitalization, cardiovascular death, and all‐cause death. Propensity score matching (1:1 ratio) using the nearest neighbor search was performed. Multivariable Cox regression with time‐weighted variables was used to identify significant associations. A 3‐arm analysis including the glucagon‐like peptide‐1 receptor agonist cohort was conducted. This cohort included 75 470 patients with type 2 diabetes (median age, 62.3±12.8 years; 55.79% men). The SGLT2I and DPP4I groups consisted of 28 753 patients and 46 717 patients, respectively. After matching, 186 and 256 patients had PAD in the SGLT2I and DPP4I groups, respectively, over a median follow‐up of 5.6 years. SGLT2I use was associated with lower risks of PAD (hazard ratio [HR], 0.79 [95% CI, 0.66–0.93]) compared with DPP4I use after adjusting for demographics, comorbidities, medications, renal function, and glycemic tests. The association remained consistent regardless of sex, age, and other metabolic diseases. In the 3‐arm analysis, the risk of PAD was not statistically different between SGLT2Is and glucagon‐like peptide‐1 receptor agonists (HR, 1.18 [95% CI, 0.52–2.68]). The results remained consistent in the competing risk and the sensitivity analyses. Conclusions: SGLT2I use among patients with type 2 diabetes was associated with lower risks of new‐onset PAD and PAD‐related outcomes when compared with DPP4Is after adjustments.

22 July 2022 in medRxiv
Verified
Preprint
Open access
PDF file
CCCheuk To Chung
Cheuk To Chung
ILIshan Lakhani
Ishan Lakhani
OCOscar Hou-In Chou
Oscar Hou-In Chou
TLTeddy Tai Loy Lee
Teddy Tai Loy Lee
CDChristopher Dee
Christopher Dee
JZJiandong Zhou
Jiandong Zhou
Background: There is much uncertainty regarding the comparative risks of cancer for T2DM patients on SGLT2I versus DPP4I. Methods: This population-based cohort study patients included T2DM patients who were administered with either SGLT2I or DPP4I between January 1st, 2015, to December 31st, 2020 in Hong Kong. Results: Amongst 60112 T2DM patients (mean baseline age: 62.1±12.4 years, male: 56.36%), 18167 patients were SGLT2I users and 41945 patients were DPP4I users. Multivariate cox regression analysis revealed that SGLT2I usage was associated with a decreased risk of all-cause mortality (HR:0.92; 95%CI:0.84-0.99; P=0.04), cancer-related mortality (HR:0.58; 95%CI:0.42-0.80; P≤0.001) and a 30% risk reduction of new-onset overall cancer (HR:0.70; 95%CI:0.59-0.84; P≤0.001). Dapagliflozin and ertugliflozin both demonstrated superiority in relation to new-onset cancer development, with the former demonstrating a lowered risk of breast cancer (HR:0.48; 95%CI:0.27-0.83; P=0.001). Conclusion: SGLT2I was associated with lower risk of all-cause mortality, cancer-related mortality and new-onset overall cancer compared to DPP4I.

22 May 2025 in Cancer Prevention Research
Verified
Journal Article
Open access
LLLifang Li
Lifang Li
HCHou In Chou
Hou In Chou
KMKar Kei Mak
Kar Kei Mak
YYYifan Yang
Yifan Yang
CCCheuk To Chung
Cheuk To Chung
Jiandong ZhouJiandong Zhou
Jiandong Zhou
Nasopharyngeal carcinoma (NPC) remains a major endemic disease in parts of Asia especially Southern China and Southest Asia, the risk factors of which are distinct from other head and neck cancers. Antidiabetic drugs have been proposed to reduce the risk of NPC. The associations between sodium–glucose cotransporter 2 inhibitors (SGLT2I) versus dipeptidyl peptidase-4 inhibitors (DPP4I) and the risks of NPC and head and neck cancer among patients with type 2 diabetes mellitus (T2DM) remain unknown. This was a population-based cohort study including patients with T2DM treated with either an SGLT2I or a DPP4I between January 1, 2015, and December 31, 2019, in Hong Kong. Propensity score matching (1:1 ratio) was performed using the nearest neighbor search. Multivariable Cox regression was applied to identify significant predictors. The primary outcome was new-onset NPC and other head and neck cancers. We found that patients with T2DM were treated with either an SGLT2I or a DPP4I between January 1, 2015, and December 31, 2019, in Hong Kong. This cohort included 75,884 patients with T2DM, among whom 28,778 patients were on an SGLT2I and 47,106 patients were on a DPP4I. After matching (57,556 patients), 106 patients developed NPC and 50 patients developed head and neck cancer. Compared with DPP4Is, SGLT2Is were associated with lower risks of NPC (HR, 0.41; 95% confidence interval, 0.21–0.81) but not of head and neck cancer (HR, 1.00; 95% confidence interval, 0.26–3.92) after adjustments. The association remained consistent in different risk models, matching approaches, and sensitivity analysis. In conclusion, this study provided real-world evidence that SGLT2Is were associated with lower risks of NPC but not of head and neck cancer when compared with DPP4Is among patients with T2DM, whereas their biological effects need future confirmation. Prevention Relevance: This study provided real-world evidence that SGLT2Is were associated with lower risks of NPC but not of head and neck cancer when compared with DPP4Is among patients with T2DM. SGLT2Is should be considered before DPP4Is about the risks of NPC in regions with high prevalence of NPC.

1 October 2025
Verified
Other
Open access
LLLifang Li
Lifang Li
HCHou In Chou
Hou In Chou
KMKar Kei Mak
Kar Kei Mak
YYYifan Yang
Yifan Yang
CCCheuk To Chung
Cheuk To Chung
Jiandong ZhouJiandong Zhou
Jiandong Zhou
Supplementary Table S5: Sensitivity analysis: Risk of the adverse outcome upon patients with CKD stage 4/5 (eGFR <30), peritoneal dialysis or haemodialysis, excluding patient with prior VT/VF/SCD, excluding patients die within 30 days after drug uses, including patients who were drug abuser, and excluding patients with financial aids, and patients with extreme 10% propensity score at the 2 end.

1 October 2025
Verified
Other
Open access
LLLifang Li
Lifang Li
HCHou In Chou
Hou In Chou
KMKar Kei Mak
Kar Kei Mak
YYYifan Yang
Yifan Yang
CCCheuk To Chung
Cheuk To Chung
Jiandong ZhouJiandong Zhou
Jiandong Zhou
Supplementary Table S8: Number of events and incidence of NPC and H&N cancer of all users and metformin users from Hong Kong diabetes patient diagnosed in 2009.

1 October 2025
Verified
Other
Open access
LLLifang Li
Lifang Li
HCHou In Chou
Hou In Chou
KMKar Kei Mak
Kar Kei Mak
YYYifan Yang
Yifan Yang
CCCheuk To Chung
Cheuk To Chung
Jiandong ZhouJiandong Zhou
Jiandong Zhou
Supplementary Figure S1: Propensity score matching comparisons and proportional hazard assumption checking with parallel lines for SGLT2I versus DPP4I before and after 1:1 matching with nearest neighbours search strategy with calliper of 0.1.